{
    "id": 3329,
    "fullName": "ERBB2 G776V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) G776V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776V confers a gain of function to the Erbb2 (Her2) protein as indicated by increased downstream Mapk signaling and colony formation (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017), transformation in cell culture (PMID: 29967253), and increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) in one of two cell lines (PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11774,
                    "pubMedId": 29967253,
                    "title": "High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967253"
                },
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "G776V",
    "createDate": "02/25/2015",
    "updateDate": "04/14/2019",
    "referenceTranscriptCoordinates": {
        "id": 170510,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39724745G>T",
        "cDna": "c.2327G>T",
        "protein": "p.G776V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5919,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) G776V in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",
            "molecularProfile": {
                "id": 3960,
                "profileName": "ERBB2 G776V"
            },
            "therapy": {
                "id": 3981,
                "therapyName": "AP32788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5195,
                    "pubMedId": null,
                    "title": "AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16745,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an ER/PR positive, ERBB2 (HER2) negative breast cancer patient harboring ERBB2 (HER2) G776V, PIK3CA H1047R, and two MAP3K1 frameshift mutations who progressed while being treated with Herceptin (trastuzumab), Perjeta (pertuzumab), and Aromasin (exemestane) demonstrated a clinical response for nearly six months when switched to Herceptin (trastuzumab), Perjeta (pertuzumab), and Abraxane (nab-paclitaxel) (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017).",
            "molecularProfile": {
                "id": 31777,
                "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 8163,
                "therapyName": "Nab-paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16744,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ER/PR positive, ERBB2 (HER2) negative breast cancer harboring ERBB2 (HER2) G776V, PIK3CA H1047R, and two MAP3K1 frameshift mutations demonstrated a positive clinical response for 13 months when treated with a combination of Herceptin (trastuzumab), Perjeta (pertuzumab) and Aromasin (exemestane) (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017).",
            "molecularProfile": {
                "id": 31777,
                "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 8162,
                "therapyName": "Exemestane + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of KRAS G12V conferred resistance to Nerlynx (neratinib) in an ovarian cancer cell line harboring ERBB2 (HER2) G776V in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35132,
                "profileName": "ERBB2 G776V KRAS G12V"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) to treatment with Nerlynx (neratinib) inhibited viability of an ovarian cancer cell line harboring ERBB2 (HER2) G776V and expressing PIK3CA H1047R in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35133,
                "profileName": "ERBB2 G776V PIK3CA H1047R"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20344,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PIK3CA H1047R conferred resistance to Nerlynx (neratinib) in an ovarian cancer cell line harboring ERBB2 (HER2) G776V in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35133,
                "profileName": "ERBB2 G776V PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20352,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of TSC1 S1043fs resulted in decreased sensitivity inhibition of cell viability by Nerlynx (neratinib) in an ovarian cancer cell line harboring ERBB2 (HER2) G776V in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35148,
                "profileName": "ERBB2 G776V TSC1 S1043fs"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20353,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) to treatment with Nerlynx (neratinib) resulted in decreased cell viability in an ovarian cancer cell line harboring ERBB2 (HER2) G776V and expressing TSC1 S1043fs in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35148,
                "profileName": "ERBB2 G776V TSC1 S1043fs"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3960,
            "profileName": "ERBB2 G776V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31777,
            "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35132,
            "profileName": "ERBB2 G776V KRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35133,
            "profileName": "ERBB2 G776V PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35148,
            "profileName": "ERBB2 G776V TSC1 S1043fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170510,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39724745G>T",
            "cDna": "c.2327G>T",
            "protein": "p.G776V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170511,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39724745G>T",
            "cDna": "c.2327G>T",
            "protein": "p.G776V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}